Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis

dc.contributor.authorXu, Chang
dc.contributor.authorLau, Colleen
dc.contributor.authorClark, Justin
dc.contributor.authorRafferty, Anna
dc.contributor.authorMills, Deborah
dc.contributor.authorRamsey, Lani
dc.contributor.authorGilbert, Brian
dc.contributor.authorDoi, Suhail A R
dc.contributor.authorFuruya Kanamori, Luis
dc.date.accessioned2024-08-06T05:47:06Z
dc.date.available2024-08-06T05:47:06Z
dc.date.issued2021
dc.date.updated2024-05-19T08:15:53Z
dc.description.abstractBackground There are a myriad of vaccine schedules for rabies pre- (PrEP) and post-exposure prophylaxis (PEP) that differ in the number and time doses, number of visits, length of schedule, and route of administration. The objective of this study was to systematically review the evidence and investigate how the differences in schedules influence titres over time. Methods Four databases were searched from inception to January 2020 for rabies PrEP and PEP studies. A dose–response meta-analysis was utilised to pool geometric mean titres (GMT) over time. Subgroup analyses by route of administration, age group, and schedule were conducted. Results 80 studies met the inclusion criteria and contributed with 191 datasets and 12,413 participants. Both intradermal (ID) and intramuscular (IM) PrEP/PEP produce adequate GMTs. Significantly lower GMT levels were achieved in older (>50yrs) compared to younger (<50yrs) participants. Short 1-week schedules were as effective as longer schedules that can take between 3 and 12 weeks to complete. Conclusions Several effective ID and IM schedules were identified, the selection of a schedule should take into account the patient’s needs, costs, availability to return for subsequent doses, and the time required to complete the schedule. Older individuals warrant special attention as they develop lower antibody response.
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn0264-410X
dc.identifier.urihttps://hdl.handle.net/1885/733714470
dc.language.isoen_AUen_AU
dc.publisherElsevier
dc.relationhttp://purl.org/au-research/grants/nhmrc/APP1158469
dc.rights© 2021 The authors
dc.sourceVaccine
dc.subjectAntibodies
dc.subjectIntradermal
dc.subjectIntramuscular
dc.subjectSeroconversion
dc.subjectSeropositive
dc.subjectTitre
dc.subjectVaccine
dc.titleImmunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis
dc.typeJournal article
local.bibliographicCitation.issue7
local.bibliographicCitation.lastpage1050
local.bibliographicCitation.startpage1044
local.contributor.affiliationXu, Chang, Qatar University
local.contributor.affiliationLau, Colleen, College of Health and Medicine, ANU
local.contributor.affiliationClark, Justin, Bond University
local.contributor.affiliationRafferty, Anna, College of Health and Medicine, ANU
local.contributor.affiliationMills, Deborah, College of Health and Medicine, ANU
local.contributor.affiliationRamsey, Lani, Travel-Bug Vaccination Clinic
local.contributor.affiliationGilbert, Brian, Travel-Bug Vaccination Clinic
local.contributor.affiliationDoi, Suhail A R, Qatar University
local.contributor.affiliationFuruya Kanamori, Luis, College of Health and Medicine, ANU
local.contributor.authoruidLau, Colleen, u5651486
local.contributor.authoruidRafferty, Anna, u5371873
local.contributor.authoruidMills, Deborah, u1092790
local.contributor.authoruidFuruya Kanamori, Luis, u5127170
local.description.embargo2099-12-31
local.description.notesImported from ARIES
local.identifier.absfor420299 - Epidemiology not elsewhere classified
local.identifier.ariespublicationa383154xPUB21519
local.identifier.citationvolume39
local.identifier.doi10.1016/j.vaccine.2021.01.023
local.identifier.scopusID2-s2.0-85099617940
local.identifier.thomsonIDWOS:000615141100007
local.publisher.urlhttps://www.sciencedirect.com/
local.type.statusPublished Version
publicationvolume.volumeNumber39

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
1-s2.0-S0264410X21000396-main.pdf
Size:
585.7 KB
Format:
Adobe Portable Document Format